Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Schaeffer, David F ^a   Owen, Daniel R ^a   Lim, Howard J ^b   Buczkowski, Andrew K ^a   Chung, Stephen W ^a   Scudamore, Charles H ^a   Huntsman, David G ^a   Ng, Sylvia S W ^a,b   Owen, David A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LIKE GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ACTIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR GROWTH; ADENOCARCINOMA; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACTINS; ADENOCARCINOMA; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77649330544     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-59     Document Type: Article

References (37)

1. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl 2001, 234:93-9.
2. Liao B, Patel M, Hu Y, Charles S, Herrick DJ, Brewer G. Targeted knockdown of the RNA-binding protein CRD-BP promotes cell proliferation via an insulin-like growth factor II-dependent pathway in human K562 leukemia cells. J Biol Chem 2004, 279:48716-24. 10.1074/jbc.M405853200, 15355996.
3. Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem 2005, 280:20086-93. 10.1074/jbc.M410036200, 15769738.
4. Huttelmaier S, Zenklusen D, Lederer M, Dictenberg J, Lorenz M, Meng X, Bassell GJ, Condeelis J, Singer RH. Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1. Nature 2005, 438:512-5. 10.1038/nature04115, 16306994.
5. Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, Vila MR, Adler G, Gress TM. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997, 14:2729-33. 10.1038/sj.onc.1201110, 9178771.
6. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002, 287:49-54. 10.1016/S0378-1119(01)00866-6, 11992722.
7. Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005, 97:87-96. 10.1042/BC20040151, 15601260.
8. Mori H, Sakakibara S, Imai T, Nakamura Y, Iijima T, Suzuki A, Yuasa Y, Takeda M, Okano H. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 2001, 64:132-43. 10.1002/jnr.1060, 11288142.
9. Brants JR, Ayoubi TA, Chada K, Marchal K, Ven WJ, Petit MM. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett 2004, 569:277-83. 10.1016/j.febslet.2004.05.075, 15225648.
10. Hammer NA, Hansen TO, Byskov AG, Rajpert-De Meyts E, Grøndahl ML, Bredkjaer HE, Wewer UM, Christiansen J, Nielsen FC. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005, 130:203-12. 10.1530/rep.1.00664, 16049158.
11. Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P, Moore GE. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet 2002, 39:575-81. 10.1136/jmg.39.8.575, 1735212, 12161597.
12. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G, Gress TM. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95-9. 10.1016/S0925-4773(99)00160-4, 10525192.
13. Wagner M, Kunsch S, Duerschmied D, Beil M, Adler G, Mueller F, Gress TM. Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. Gastroenterology 2003, 124:1901-14. 10.1016/S0016-5085(03)00402-5, 12806623.
14. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol 2008, 52:133-8.
15. Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol 2007, 35:700-4. 10.1002/dc.20739, 17924416.
16. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-64. 10.1016/S1470-2045(06)70732-X, 16814207.
17. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112:1471-9. 10.1002/cncr.23296, 2792740, 18260086.
18. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih I, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathol 2009, 22(3):469-75.
19. Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöppel G. The grade of pancreatic ductal adenocarcinomas is an independent prognostic factor and is superior to the immunohistochemical assessment of prolifertion. J Pathol 2000, (191):154-161. 10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C, 10861575.
20. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008, 32:304-15. 10.1097/PAS.0b013e3181483ff8, 18223334.
21. Köbel M, Weichert W, Crüwell K, Schmitt WD, Lautenschläger C, Hauptmann S. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch 2004, 445:456-464. 10.1007/s00428-004-1095-0, 15375658.
22. Liu CL, Montgomery KD, Natkunam Y, West RB, Nielsen TO, Cheang MC, Turbin DA, Marinelli RJ, Rijn M, Higgins JP. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol 2005, 18:1641-1648.
23. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007, 38:555-63. 10.1016/j.humpath.2006.11.011, 17316760.
24. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007, 20:242-7. 10.1038/modpathol.3800735, 17192788.
25. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008, 14:1701-6. 10.1158/1078-0432.CCR-07-2039, 18347170.
26. Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki KA. comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001, 60(2):151-61. 10.1159/000055313, 11244331.
27. Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, Nielsen FC. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006, 25:1456-68. 10.1038/sj.emboj.7601039, 1440323, 16541107.
28. Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, Singer RH, Pikarsky E, Yisraeli JK. A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol 2008, 215:445-56. 10.1002/path.2376, 18535985.
29. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched 1 heterozygous mice. Cancer Res 2008, 68:8788-95. 10.1158/0008-5472.CAN-08-2135, 2597356, 18974121.
30. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998, 58:348-51.
31. Björndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ, Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005, 102:15593-8. 10.1073/pnas.0507865102, 1266150, 16230630.
32. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 1999, 96:3098-103. 10.1073/pnas.96.6.3098, 15901, 10077643.
33. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997, 94:5810-3. 10.1073/pnas.94.11.5810, 20862, 9159156.
34. Lamharzi N, Schally AV, Koppán M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998, 95:8864-8. 10.1073/pnas.95.15.8864, 21168, 9671770.
35. Lamm GM, Christofori G. Impairment of survival factor function potentiates chemotherapy induced apoptosis in tumor cells. Cancer Res 1998, 58:8017.
36. Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003, 88:887-94. 10.1038/sj.bjc.6600806, 2377073, 12644826.
37. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, Pappen B, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA. Phase I Trial of sequential administration of recombinant DNA and adenovirus expression L523S protein in early stage non-small-cell lungcancer. Mol Ther 2006, 13:1185-91. 10.1016/j.ymthe.2006.01.013, 16581300.